243 related articles for article (PubMed ID: 29118397)
21. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
[TBL] [Abstract][Full Text] [Related]
22. Role of the polycystic kidney disease domain in matriptase chaperone activity and localization of hepatocyte growth factor activator inhibitor-1.
Yamashita F; Kaieda T; Shimomura T; Kawaguchi M; Lin CY; Johnson MD; Tanaka H; Kiwaki T; Fukushima T; Kataoka H
FEBS J; 2022 Jun; 289(12):3422-3439. PubMed ID: 35020274
[TBL] [Abstract][Full Text] [Related]
23. Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase.
Domoto T; Takino T; Guo L; Sato H
Cancer Sci; 2012 Mar; 103(3):448-54. PubMed ID: 22118498
[TBL] [Abstract][Full Text] [Related]
24. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1.
Denda K; Shimomura T; Kawaguchi T; Miyazawa K; Kitamura N
J Biol Chem; 2002 Apr; 277(16):14053-9. PubMed ID: 11805118
[TBL] [Abstract][Full Text] [Related]
25. Identification of the matriptase second CUB domain as the secondary site for interaction with hepatocyte growth factor activator inhibitor type-1.
Inouye K; Tsuzuki S; Yasumoto M; Kojima K; Mochida S; Fushiki T
J Biol Chem; 2010 Oct; 285(43):33394-33403. PubMed ID: 20682770
[TBL] [Abstract][Full Text] [Related]
26. Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Chou FP; Chen YW; Zhao XF; Xu-Monette ZY; Young KH; Gartenhaus RB; Wang JK; Kataoka H; Zuo AH; Barndt RJ; Johnson M; Lin CY
Am J Pathol; 2013 Oct; 183(4):1306-17. PubMed ID: 24070417
[TBL] [Abstract][Full Text] [Related]
27. Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Kiyomiya K; Lee MS; Tseng IC; Zuo H; Barndt RJ; Johnson MD; Dickson RB; Lin CY
Am J Physiol Cell Physiol; 2006 Jul; 291(1):C40-9. PubMed ID: 16467405
[TBL] [Abstract][Full Text] [Related]
28. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor.
Kawaguchi T; Qin L; Shimomura T; Kondo J; Matsumoto K; Denda K; Kitamura N
J Biol Chem; 1997 Oct; 272(44):27558-64. PubMed ID: 9346890
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.
Kato M; Hashimoto T; Shimomura T; Kataoka H; Ohi H; Kitamura N
J Biochem; 2012 Feb; 151(2):179-87. PubMed ID: 22023801
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells.
Lee MS; Kiyomiya K; Benaud C; Dickson RB; Lin CY
Am J Physiol Cell Physiol; 2005 Apr; 288(4):C932-41. PubMed ID: 15590895
[TBL] [Abstract][Full Text] [Related]
31. Matriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in Lactation.
Lai CH; Lai YJ; Chou FP; Chang HH; Tseng CC; Johnson MD; Wang JK; Lin CY
PLoS One; 2016; 11(4):e0152904. PubMed ID: 27043831
[TBL] [Abstract][Full Text] [Related]
32. Differential subcellular localization renders HAI-2 a matriptase inhibitor in breast cancer cells but not in mammary epithelial cells.
Chang HH; Xu Y; Lai H; Yang X; Tseng CC; Lai YJ; Pan Y; Zhou E; Johnson MD; Wang JK; Lin CY
PLoS One; 2015; 10(3):e0120489. PubMed ID: 25786220
[TBL] [Abstract][Full Text] [Related]
33. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor.
Oberst MD; Williams CA; Dickson RB; Johnson MD; Lin CY
J Biol Chem; 2003 Jul; 278(29):26773-9. PubMed ID: 12738778
[TBL] [Abstract][Full Text] [Related]
34. 3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation.
Ye F; Chen S; Liu X; Ye X; Wang K; Zeng Z; Su Y; Zhang XK; Zhou H
J Cell Mol Med; 2019 Jan; 23(1):155-166. PubMed ID: 30370662
[TBL] [Abstract][Full Text] [Related]
35. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
[TBL] [Abstract][Full Text] [Related]
36. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor.
Benaud C; Dickson RB; Lin CY
Eur J Biochem; 2001 Mar; 268(5):1439-47. PubMed ID: 11231297
[TBL] [Abstract][Full Text] [Related]
37. Antithrombin regulates matriptase activity involved in plasmin generation, syndecan shedding, and HGF activation in keratinocytes.
Chen YW; Xu Z; Baksh AN; Wang JK; Chen CY; Swanson R; Olson ST; Kataoka H; Johnson MD; Lin CY
PLoS One; 2013; 8(5):e62826. PubMed ID: 23675430
[TBL] [Abstract][Full Text] [Related]
38. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Oberst M; Anders J; Xie B; Singh B; Ossandon M; Johnson M; Dickson RB; Lin CY
Am J Pathol; 2001 Apr; 158(4):1301-11. PubMed ID: 11290548
[TBL] [Abstract][Full Text] [Related]
39. Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1.
Tseng IC; Chou FP; Su SF; Oberst M; Madayiputhiya N; Lee MS; Wang JK; Sloane DE; Johnson M; Lin CY
Am J Physiol Cell Physiol; 2008 Aug; 295(2):C423-31. PubMed ID: 18550704
[TBL] [Abstract][Full Text] [Related]
40. Loss of the matriptase inhibitor HAI-2 during prostate cancer progression.
Bergum C; List K
Prostate; 2010 Sep; 70(13):1422-8. PubMed ID: 20687215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
